Skip to content

Predictive Validity of the Chelsea Critical Care Physical Assessment Tool (CPAx) for Regaining Autonomy Three Months After ICU Discharge

Etude de validité Predictive du Chelsea Critical Care Physical Assessment Tool (CPAx) Quant au Retour de l'Autonomie à la Marche 3 Mois après la Sortie de réanimation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07167121
Acronym
CPAx-Predict
Enrollment
29
Registered
2025-09-11
Start date
2025-09-01
Completion date
2026-08-30
Last updated
2026-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ICU Acquired Weakness, Intensive Care Neuropathy

Keywords

ICU, Physiotherapy, ICU Acquired Weakness, CPAx, Predictive Validity, Test

Brief summary

This single-center observational study aims to explore the relationship between the CPAx score (Chelsea Critical Care Physical Assessment Tool), measured at ICU discharge, and the 6-minute walk test (6MWT) distance performed 3 months after discharge. The study targets patients who experienced prolonged mechanical ventilation and were admitted to the ICU at CHI Elbeuf-Louviers-Val-de-Reuil. Eligible participants must show signs of malnutrition, muscular weakness, or post-traumatic stress symptoms. Data collection includes the CPAx score, 6MWT distance, MRC score, and relevant clinical and demographic information. The primary objective is to determine whether the CPAx score can predict long-term functional recovery and guide post-ICU rehabilitation strategies. Participants will be evaluated during routine follow-up in the day hospital. This non-interventional study poses minimal risk to participants.

Interventions

DIAGNOSTIC_TESTCPAx

Evaluation of : Respiratory function Cough Moving within the bed Supine to sitting on the edge of the bed Dynamic sitting Standing balance Sit to stand (starting position ≥ 90°) Transfering from bed to chair Stepping Grip strength (predicted mean for age and gender on the strongest hand)

Sponsors

Centre Hospitalier Intercommunal Elbeuf-Louviers-Val de Reuil
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient affiliated with, or entitled to benefit from, a French social security system. * Patient who has received clear and comprehensive information about the study * Age ≥ 18 years. * Having received at least 48 hours of invasive mechanical ventilation. * Previous hospitalization in the intensive care unit (ICU) at CHI Elbeuf-Louviers-Val-de-Reuil. * Prescription of physiotherapy during the ICU stay. * Eligible for the 3-month post-ICU follow-up in the day hospital based on at least one of the following criteria: * Mechanical ventilation or catecholamine treatment (norepinephrine) for ≥ 5 days; * Weight loss ≥ 5% during hospitalization (criterion for malnutrition); * Significant muscle weakness (MRC score \< 28/60); * Presence of post-traumatic stress symptoms related to ICU stay (evaluated by the psychologist). * Ability to walk (with or without assistive devices) prior to ICU admission.

Exclusion criteria

* Patient not affiliated with the French national health insurance system. * Documented pre-existing cognitive impairment likely to limit understanding of instructions and participation in functional assessments (e.g., dementia, intellectual disability, severe uncontrolled psychiatric disorder). * History of disabling chronic neuromuscular disease (e.g., amyotrophic lateral sclerosis, myopathy, progressive chronic polyneuropathy). * History of major pre-existing locomotor impairment preventing autonomous walking (e.g., paraplegia, uncompensated disabling arthropathy). * Refusal to participate in the study or withdrawal of consent at any time. * Person under legal guardianship, curatorship, or any other legal protection measure. * Simultaneous participation in another interventional study likely to interfere with the evaluation criteria of the present study. * Medical contraindication to performing the 6-minute walk test at 3 months (e.g., cardiovascular decompensation, acute pulmonary disease, persistent hemodynamic instability).

Design outcomes

Primary

MeasureTime frameDescription
Predictive validity beetween CPAx test and 6MWTThree months after dischargeEvaluation Criteria: The statistical analysis will primarily aim to assess the correlation between the CPAx score, a discrete quantitative variable (ranging from 0 to 50), and the distance covered in the 6-Minute Walk Test (6MWT), a continuous quantitative variable. The alpha risk is set at 5% and the beta risk at 80%. A sample size of 25 patients has been determined to allow for an initial estimate, accounting for an anticipated 20% loss to follow-up, in line with recommendations for feasibility studies in intensive care settings. Method : The choice of correlation test will depend on data distribution: * If CPAx and 6MWT distributions are normal (as verified by Shapiro-Wilk or Kolmogorov-Smirnov tests), Pearson's correlation will be used. * In the absence of normality or in the presence of significant skewness, Spearman's correlation (a non-parametric test) will be preferred.

Secondary

MeasureTime frameDescription
Correlation between CPAx and SF-36 questionnaryThree months after dischargeAnalysis of the correlation between each item of the CPAx and the results of the 6-minute walk test three months after ICU discharge. Analysis of the correlation between individual CPAx item scores and SF-36 questionnaire results three months after ICU discharge Methods for Secondary Outcomes: * Correlation between CPAx items and 6MWT: Each CPAx item will be analyzed individually as a discrete ordinal variable. Spearman's correlation will be used. * Correlation between overall CPAx score and SF-36 dimensions: These correlations will be assessed using Spearman's test, unless normality of SF-36 subscales is confirmed. Exploratory analyses using simple or multiple linear regression may also be conducted to model the relationship between CPAx and 6MWT, adjusting for clinical variables (age, BMI, duration of ventilation, etc.).

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 3, 2026